Domain Therapeutics, a leading GPCR immunooncology company, has recently welcomed Sean A. MacDonald as its new Chief Business Officer (CBO), marking a significant milestone in the company’s mission to advance precision research in cancer immunotherapy.
MacDonald’s appointment underscores Domain Therapeutics’ commitment to driving innovation and accelerating the clinical development of its drug candidates targeting GPCR-mediated immunosuppression. With over 20 years of senior executive experience in the life science industry, MacDonald brings a wealth of expertise in executing multiple deals and driving business growth strategies.
“We are thrilled to have Sean A. MacDonald join our team as Chief Business Officer,” stated Dr. Anthony G. Johnson, President and CEO of Domain Therapeutics. “His proven track record and unparalleled knowledge of the biotech landscape will be invaluable as we navigate the complex challenges of advancing our unique precision research approach in cancer immunotherapy.”
As Chief Business Officer, MacDonald will be pivotal in shaping Domain Therapeutics’ strategy, business development initiatives, and communications efforts. His leadership will drive value across the company’s growing portfolio of assets and partnerships, ultimately aiming to deliver differentiated GPCR-targeted cancer immunotherapy to needy patients.
“I am excited to join Domain Therapeutics at such a pivotal moment in the company’s evolution,” expressed Sean A. MacDonald. “I look forward to leveraging my experience and expertise to contribute to Domain’s growth and presence in the US market while advancing our mission to beat resistance and defeat cancer through innovative precision research.”
MacDonald’s appointment follows the recent strategic appointments of Dr. Anthony G. Johnson as President and CEO and Michael Gottlieb as Chairman of the Board, further solidifying Domain Therapeutics’ position as a global leader in cancer therapeutics.
